Zacks Investment Research Downgrades Histogenics (HSGX) to Sell
Histogenics (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Several other research firms have also weighed in on HSGX. HC Wainwright reiterated a “buy” rating and set a $3.50 target price on shares of Histogenics in a report on Monday, August 13th. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. Needham & Company LLC lifted their target price on Histogenics to $5.00 and gave the stock a “buy” rating in a report on Thursday, September 6th. Finally, BTIG Research downgraded Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target on the stock. in a research note on Wednesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $3.45.
Histogenics (NASDAQ:HSGX) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.10. On average, equities analysts predict that Histogenics will post -0.71 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HSGX. BlackRock Inc. raised its stake in shares of Histogenics by 72.0% in the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 22,927 shares during the period. DRW Securities LLC acquired a new stake in shares of Histogenics in the 2nd quarter valued at about $242,000. JPMorgan Chase & Co. acquired a new stake in shares of Histogenics in the 1st quarter valued at about $320,000. Finally, Renaissance Technologies LLC raised its stake in shares of Histogenics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 22,133 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.